Pharmaceutical industry – Page 45
-
Business
Biotech bounced back in 2013, says report
R&D investment increasing, but industry needs to use its cash more wisely
-
Business
Shire fends off AbbVie takeover bid
Board says deal undervalues the company and its growth potential
-
Business
Medtronic to buy Covidien for $43bn
Tax inversion deal continues consolidation theme among medical device makers
-
Business
Novo Nordisk to create 6000 jobs by 2022
Half of the new Danish employees will be in R&D roles
-
Business
Pharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
Business
Drug giants settle mismarketing lawsuits
Pfizer and GSK settle claims over promoting drugs for unapproved uses in the US
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
Opinion
Messy megamergers
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
-
Business
Chinese-made DNA sequencer aims to challenge foreign dominance
Domestic instrument pitching for a slice of the world’s fastest growing genome sequencing market
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
Feature
Reaching out
Andy Extance surveys how pharma uses outsourcing in a variety of different ways
-
Business
Novartis enhances its focus with eyecare deal
Swiss firm buys rights to wet AMD drug from Ophthotech for up to $1bn
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders
-
Business
Lilly protests $450m Brazilian fine
Firm says chemicals employees were allegedly exposed to were never used at site
-
Business
Chinese police hand GSK bribery case to prosecutors
Investigation alleges senior manager ordered staff to hand out bribes
-
Business
Pfizer presses hard for AstraZeneca deal
Executives face down international controversy over tax schemes and previous post-merger record